1. Home
  2. News
  3. Orthocell Ltd
  4. First Surgical Use of Remplir in US$1.6 Billion US Market
More Orthocell Ltd news
Orthocell LtdASX: OCC

First Surgical Use of Remplir in US$1.6 Billion US Market

Jun 26, 2025 at 11:22 PM EDT · Issued by Orthocell Ltd

Filed with ASX · Jun 26, 2025 at 11:22 PM EDT · 3 pages · English

On 6ix: 6ix.com/news/first-surgical-use-of-remplir-in-usdollar1.6-billion-us-market

Orthocell Ltd on 6ix

Story so far

  • Compelling Data Highlights Remplir Competitive AdvantageJun 19, 2025
  • Remplir Approved to Commence Sales in the Hong Kong MarketMay 12, 2025
  • 12 Distributors Signed for Remplir Covering 21 States in USMay 9, 2025

Earlier from Orthocell

  • Compelling Data Highlights Remplir Competitive AdvantageJun 18, 2025
  • Remplir Approved to Commence Sales in the Hong Kong MarketMay 11, 2025
  • 12 Distributors Signed for Remplir Covering 21 States in USMay 8, 2025
  • Remplir Approved to Commence Sales in US$75m Canadian MarketApr 29, 2025
  • Replacement Trading HaltApr 29, 2025

Later from Orthocell

  • Record Revenue of $2.73m in June 25 Quarter up 22.8% QoQJun 30, 2025
  • Orthocell Announces First US Remplir Sales RevenueJul 9, 2025
  • Appendix 4E & Annual ReportAug 29, 2025
  • Compelling 81% Success Rate for RemplirSep 7, 2025
  • Remplir™ Study Delivers Compelling 81% Success RateSep 8, 2025
All Orthocell news releases↗

Follow Orthocell into a list and get an email when it puts out news.

Follow Orthocell
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer